SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEvoke Plc Regulatory News (EVOK)

Share Price Information for Evoke Plc (EVOK)

Share Price is delayed by 15 minutes
Get Live Data
46.20    -0.55 (-1.18%)
Bid:
46.30
Ask:
46.50
Spread: 0.20 (0.432%)
Market Cap: £207.96m
EVOK Live PriceLast checked at - London Stock Exchange

Intraday Evoke Plc Share Chart

Statement regarding media speculation

20 Apr 2026 07:01

RNS Number : 0950B
Evoke PLC
20 April 2026
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

FOR IMMEDIATE RELEASE

20 April 2026

evoke plc

("evoke" or the "Company")

Statement regarding media speculation

evoke notes the recent media speculation and confirms that it is in discussions with Bally's Intralot S.A. ("Bally's Intralot") regarding a possible offer for the entire issued and to be issued share capital of the Company at a price of 50 pence per share (the "Proposal"). The Proposal is expected to comprise an all-share combination with a partial cash alternative.

There can be no certainty that an offer will be made or as to the terms on which any offer might be made.

The Board of evoke is evaluating the possible offer together with its financial advisers, Morgan Stanley and Rothschild & Co.

evoke shareholders are advised not to take any action in relation to the Proposal.

A further announcement will be made when appropriate.

Bally's Intralot has confirmed to the Company that it will, by no later than 5.00 p.m. (London time) on 18 May 2026, being 28 days after the date of this announcement, either announce a firm intention to make an offer for the Company or announce that it does not intend to make an offer. This deadline can be extended with the consent of the Company. 

Bally's Intralot has confirmed that any firm offer, if made, would be subject to customary conditions and approvals and that it reserves the right to vary the terms of any such offer, including the price, the form and mix of consideration and the structure of the transaction.

This announcement has been made with the consent of the Bally's Intralot Board.

The person responsible for arranging the release of this announcement on behalf of the Company is Fredrik Ekdahl.

 

For further information, please contact:

evoke

Per Widerström, CEO

Sean Wilkins, CFO

James Finney, Director of IR

Tel: +44 (0) 800 029 3050

Media - Hudson Sandler

Alex Brennan / Hattie Dreyfus / Andy Richards

Tel: +44 (0) 20 7796 4133

Morgan Stanley

Laurence Hopkins

Ben Grindley

Paolo Della Rovere

Tel: +44 (0) 20 7425 8000

Rothschild & Co.

Daniel Ross

Edward Duckett

Ashley Gillard

Tel: +44 (0) 20 7280 5000

The City Code on Takeovers and Mergers

The City Code on Takeovers and Mergers (the "Code") does not apply to the Company as it is registered in Gibraltar. As a result, a takeover offer for the Company will not be regulated by the UK Panel on Takeovers and Mergers (the "Panel"). The Company's articles of association contain certain provisions requiring the Company to use its reasonable endeavours to apply the rules of the Code to a takeover offer for the Company (except where not in the best interest of the Company to do so), although these do not provide the full protections afforded by the Code and the enforcement of such provisions is the responsibility of the Company, not the Panel. Accordingly, shareholders of the Company are reminded that the Panel does not have responsibility, in relation to the Company, for ensuring compliance with the Code and is not able to answer shareholders' questions in that regard.

Publication on website

A copy of this announcement will be available at www.evokeplc.com, by no later than 12 noon (London time) on 21 April 2026. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Number of shares in issue

As at the close of business on 17 April 2026 (being the business day prior to the date of this announcement), evoke confirms that it had in issue 450,634,446 ordinary shares of GBP £0.005 each (excluding shares held in treasury) with voting rights and admitted to trading on the main market of the London Stock Exchange under the ISIN code GI000A0F6407.

Further information

This announcement is not intended to and does not constitute an offer to buy or the solicitation of an offer to subscribe for or sell or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction. The release, publication or distribution of this announcement in whole or in part, directly or indirectly, in, into or from certain jurisdictions may be restricted by law and therefore persons in such jurisdictions should inform themselves about and observe such restrictions.

Morgan Stanley & Co. International plc ("Morgan Stanley"), which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the PRA and the Financial Conduct Authority ("FCA") in the United Kingdom, is acting exclusively for evoke and for no one else in connection with the possible offer and neither Morgan Stanley nor any of its affiliates, nor their respective directors, officers, employees or agents will be responsible to anyone other than evoke for providing the protections afforded to its clients or for providing advice in relation to the possible offer, the contents of this announcement or any other matters referred to in this announcement.

N.M. Rothschild & Sons Limited ("Rothschild & Co"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for evoke and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than evoke for providing the protections afforded to its clients or for providing advice in connection with the subject matter of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPCKZGZDKGRGVZG
Date   Source Headline
12th Jun 20263:48 pmRNSAwards granted under the LTIP
9th Jun 20263:30 pmRNSNotification of Transactions by PDMR
8th Jun 202612:18 pmRNSResults of AGM 8 June 2026
5th Jun 20267:00 amRNSRecommended all-share acquisition of evoke plc
4th Jun 20265:55 pmRNSHolding(s) in Company
1st Jun 20267:00 amRNSTotal Voting Rights
18th May 20264:35 pmRNSExtension of Firm Offer Deadline
11th May 20267:00 amRNSPublication of Notice of AGM
1st May 20267:00 amRNSTotal Voting Rights & Correction
30th Apr 20267:00 amRNSFY25 Results
28th Apr 20262:11 pmRNSDelay to publication of FY25 audited results
20th Apr 20267:01 amRNSStatement regarding media speculation
14th Apr 20267:00 amRNSBlock Listing Six Monthly Return
1st Apr 20269:56 amRNSTotal Voting Rights
31st Mar 202612:34 pmRNSHolding(s) in Company
18th Mar 20267:00 amRNSNotice of FY25 Results
2nd Mar 20267:00 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSTotal Voting Rights
27th Jan 20267:00 amRNS2025 Post-close Trading Update
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
18th Dec 20257:00 amRNSNotice of FY 2025 Trading Update
17th Dec 20254:40 pmRNSHolding(s) in Company
10th Dec 202510:53 amRNSStrategic Review
1st Dec 20257:00 amRNSTotal Voting Rights
26th Nov 20255:45 pmRNSResponse to the UK Budget
3rd Nov 20257:00 amRNSTotal Voting Rights
28th Oct 20257:00 amRNSQ3 2025 trading update
21st Oct 20257:00 amRNSBoard Change
14th Oct 20257:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
7th Oct 20257:00 amRNSCommittee Update
1st Oct 20257:00 amRNSTotal Voting Rights
25th Sep 20257:00 amRNSNotice of Q3 2025 trading update
11th Sep 20257:00 amRNSPricing of an offering of Senior Secured Notes
1st Sep 20257:00 amRNSTotal Voting Rights
13th Aug 20257:00 amRNSH1 2025 Interim Results
4th Aug 20257:00 amRNSInvestor Meet Company Presentation
1st Aug 20257:00 amRNSTotal Voting Rights
22nd Jul 20257:00 amRNSH1 2025 Post-Close Trading Update
16th Jul 20257:00 amRNSNotice of H1 2025 trading update
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20257:00 amRNSDirector Declaration
18th Jun 20258:28 amRNSDirector Declaration
2nd Jun 20257:00 amRNSTotal Voting Rights
28th May 202512:36 pmRNSResults of AGM 28 May 2025
28th May 20257:00 amRNSEstablishment of a Technology Committee
27th May 20255:39 pmRNSPurchase of Annual Bonus shares
1st May 20257:00 amRNSTotal Voting Rights
30th Apr 20255:53 pmRNSNotification of Transactions by PDMR
25th Apr 20258:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.